HM2023-43: A Phase 2 Trial of Tafasitamab in Combination With Lenalidomide+Rituximab in Treatment-naive Follicular Lymphoma and Marginal Zone Lymphoma
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Tafasitamab (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms HM2023-43
- 04 Feb 2025 New trial record